New Two-Step transplant aims to cut death risk in blood cancer patients
NCT ID NCT05031897
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 34 times
Summary
This phase 2 trial tests a two-step stem cell transplant using lower doses of radiation and chemotherapy before the transplant. The goal is to reduce treatment-related deaths in people with various blood cancers like leukemia, lymphoma, and myeloma. About 63 participants will receive this modified approach to see if it is safer than standard transplants.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sidney Kimmel Cancer Center at Thomas Jefferson University
RECRUITINGPhiladephia, Pennsylvania, 19107, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Fludarabine, cyclophosphamide, total-body irradiation, donor lymphocyte infusion
What this could lead to
If successful, this approach could lower the risk of death from the transplant itself, making stem cell transplants safer for people with blood cancers.
What could go wrong
This is a mid-stage trial with only 63 participants, so results may not apply to everyone. There is still a risk of relapse or serious side effects from the transplant.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.